GURUFOCUS.COM » STOCK LIST » USA » NAS » Amgen Inc (NAS:AMGN) » Definitions » EV-to-Revenue
Switch to:

Amgen (NAS:AMGN) EV-to-Revenue

: 6.82 (As of Today)
View and export this data going back to 1983. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Amgen's enterprise value is $179,600 Mil. Amgen's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 was $26,330 Mil. Therefore, Amgen's EV-to-Revenue for today is 6.82.

The historical rank and industry rank for Amgen's EV-to-Revenue or its related term are showing as below:

AMGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.35   Med: 5.55   Max: 7.23
Current: 6.82

During the past 13 years, the highest EV-to-Revenue of Amgen was 7.23. The lowest was 3.35. And the median was 5.55.

AMGN's EV-to-Revenue is ranked worse than
79.96% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 2.42 vs AMGN: 6.82

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2022-12-09), Amgen's stock price is $278.65. Amgen's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $48.10. Therefore, Amgen's PS Ratio for today is 5.79.


Amgen (NAS:AMGN) EV-to-Revenue Historical Data

The historical data trend for Amgen's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.22 5.36 7.00 6.11 5.81

Amgen Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.62 5.81 6.06 6.04 5.60

Amgen (NAS:AMGN) EV-to-Revenue Competitive Comparison

For the Drug Manufacturers - General subindustry, Amgen's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Amgen (NAS:AMGN) EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Amgen's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Amgen's EV-to-Revenue falls into.



Amgen EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Amgen's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=179600.214/26330
=6.82

Amgen's current Enterprise Value is $179,600 Mil.
Amgen's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $26,330 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amgen  (NAS:AMGN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Amgen's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=278.65/48.102
=5.79

Amgen's share price for today is $278.65.
Amgen's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.10.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amgen EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Amgen's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (NAS:AMGN) Business Description

Amgen logo
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Executives
Miller Derek officer: SVP, Human Resources ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Khosla Rachna officer: SVP, Business Development ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Ishrak Omar director 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432
Louie Linda H. officer: VP, Finance & CAO ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Miles Amy E director
Grygiel Nancy A. officer: SVP & CCO ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Griffith Peter H. officer: EVP & CFO ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Gordon Murdo officer: EVP Global Commercial Ops C/O BRISTOL-MYERS SQUIBB COMPANY 345 PARK AVE NEW YORK NY 10154
Reese David M officer: EVP, Research and Development ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Druker Brian director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Austin Wanda M director 6001 BOLLINGER CANYON ROAD SAN RAMON CA 94583
Holley Charles M director
Johnston Lori A officer: SVP, HR C/O AMGEN INC. ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Kullman Ellen Jamison director UNITED TECHNOLOGIES CORP 10 FARM SPRINGS ROAD FARMINGTON CT 06032
Santos Esteban officer: EVP, Operations ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320

Amgen (NAS:AMGN) Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership